Becton, Dickinson and Company (NYSE:BDX) EVP Sells $399,269.15 in Stock

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael David Garrison sold 1,715 shares of the company's stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the transaction, the executive vice president now directly owns 5,381 shares of the company's stock, valued at $1,252,750.61. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Becton, Dickinson and Company Stock Performance

Shares of BDX traded down $0.79 during mid-day trading on Wednesday, reaching $233.81. The company's stock had a trading volume of 2,721,501 shares, compared to its average volume of 1,380,877. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. Becton, Dickinson and Company has a 1-year low of $229.40 and a 1-year high of $287.32. The business has a 50-day simple moving average of $238.98 and a two-hundred day simple moving average of $240.76. The stock has a market cap of $67.55 billion, a P/E ratio of 55.59, a PEG ratio of 1.93 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, beating analysts' consensus estimates of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The business had revenue of $4.71 billion for the quarter, compared to analysts' expectations of $4.73 billion. During the same quarter in the prior year, the business earned $2.98 EPS. The firm's revenue for the quarter was up 2.6% on a year-over-year basis. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Monday, June 10th will be paid a $0.95 dividend. The ex-dividend date is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a yield of 1.63%. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 90.05%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. OFI Invest Asset Management bought a new position in Becton, Dickinson and Company during the third quarter worth about $25,000. Livelsberger Financial Advisory bought a new position in shares of Becton, Dickinson and Company during the fourth quarter worth approximately $27,000. OLD Point Trust & Financial Services N A acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $29,000. DiNuzzo Private Wealth Inc. acquired a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $30,000. Finally, Scarborough Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $32,000. 86.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Raymond James upped their price target on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 3rd. Barclays boosted their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an "overweight" rating in a research report on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.